Drugs in the Pipeline
While the CRL did not raise clinical concerns, the Agency noted that certain conditions related to the tablet coating process needed to be resolved.
News
The study authors focused on 4 pharmacologic classes: glucocorticoids, antiretroviral therapies, newer atypical antipsychotics, and immune checkpoint inhibitors.
Drug Monograph
Olanzapine, samidorphan; 5mg/10mg, 10mg/10mg, 15mg/10mg, 20mg/10mg; tabs.
Select the therapeutic use below to view the corresponding drug monograph
Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.
News
Lybalvi is an atypical antipsychotic comprised of samidorphan co-formulated with olanzapine in a single bilayer tablet.
Drug Monograph
Olanzapine, fluoxetine (as HCl); 3mg/25mg, 6mg/25mg, 6mg/50mg, 12mg/50mg; caps.
Select the therapeutic use below to view the corresponding drug monograph
Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.
Drug Monograph
Olanzapine 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg; tabs.
Select the therapeutic use below to view the corresponding drug monograph
Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.
Drug Monograph
Olanzapine extended-release 210mg/vial, 300mg/vial, 405mg/vial; pwd for susp; for IM inj after reconstitution.
Select the therapeutic use below to view the corresponding drug monograph
Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.
Drug Monograph
Olanzapine 5mg, 10mg, 15mg, 20mg; orally-disintegrating tabs; contains phenylalanine.
Select the therapeutic use below to view the corresponding drug monograph
Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.
Drug Monograph
Olanzapine 10mg/vial; IM inj after reconstitution.
Select the therapeutic use below to view the corresponding drug monograph
Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.
News
The likelihood of help or harm, also known as the risk/benefit ratio, was found to be more favorable for lithium.